Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). Materials and Methods The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lympho- cyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Results Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ! 46.5, ! 11.45, and ! 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ! 205.4 predicted non- complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confi- dence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. Conclusion CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
Abstract
Purpose We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). Materials and Methods The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lympho- cyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Results Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ! 46.5, ! 11.45, and ! 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ! 205.4 predicted non- complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confi- dence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. Conclusion CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
참고문헌 (25)
- 서동훈, "Major clinical research advances in gynecologic cancer in 2013", Journal of Gynecologic Oncology, 25(3), pp.236~248 (2014), 대한부인종양학회
- 김장흡, "Müllerian inhibiting substance", anti-Müllerian hormone: A novel treatment for gynecologic tumors, 2014, pp.57(05), 343~357[DOI]
- Rustin GJ, "Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)", Int J Gynecol Cancer, 21, pp.419~423 (2011)
- Tian C, "CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers : a Gynecologic Oncology Group study", Cancer, 115, pp.1395~1403 (2009)
- Eltabbakh GH, "Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma", J Surg Oncol, 93, pp.379~386 (2006)
- Shan W, "The inflammatory network : bridging senescent stroma and epithelial tumorigenesis", Front Biosci(Landmark Ed), 14, pp.4044~4057 (2009)
- den Ouden M, "Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours", Eur J Obstet Gynecol Reprod Biol, 72, pp.73~77 (1997)
- Kim SI, "Impact of underweight after treatment on prognosis of advancedstage ovarian cancer", J Immunol Res, 2014, pp.349546~ (2014)
- Asher V, "Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer", Clin Transl Oncol, 13, pp.499~503 (2011)
- Jilma B, "Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin", Am J Respir Crit Care Med, 159, pp.857~863 (1999)
- Balkwill F, "Inflammation and cancer : back to Virchow?", Lancet, 357, pp.539~545 (2001)
- Williams KA, "Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer", Gynecol Oncol, 132, pp.542~550 (2014)
- Supachai Raungkaewmanee, "Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer", Journal of Gynecologic Oncology, 23(4), pp.265~273 (2012), 대한부인종양학회
- Cho H, "Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment", Cancer Immunol Immunother, 58, pp.15~23 (2009)
- Milne K, "Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes", J Transl Med, 10, pp.33~ (2012)
- Bishara S, "Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer", Eur J Obstet Gynecol Reprod Biol, 138, pp.71~75 (2008)
- Ho CM, "Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma", Gynecol Oncol, 88, pp.394~399 (2003)
- Behbakht K, "Clinical characteristics of clear cell carcinoma of the ovary", Gynecol Oncol, 70, pp.255~258 (1998)
- Fader AN, "The prognostic significance of pre-and post-treatment CA-125 in grade 1 serous ovarian carcinoma : a gynecologic Oncology Group study", Gynecol Oncol, 132, pp.560~565 (2014)
- Jain S, "Platelets : linking hemostasis and cancer", Arterioscler Thromb Vasc Biol, 30, pp.2362~2367 (2010)
- Nieswandt B, "Lysis of tumor cells by natural killer cells in mice is impeded by platelets", Cancer Res, 59, pp.1295~1300 (1999)
- Buergy D, "Tumor-platelet interaction in solid tumors", Int J Cancer, 130, pp.2747~2760 (2012)
- Gooden MJ, "The prognostic influence of tumour-infiltrating lymphocytes in cancer : a systematic review with meta-analysis", Br J Cancer, 105, pp.93~103 (2011)
- Templeton AJ, "Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors : a systematic review and metaanalysis", J Natl Cancer Inst, 106 (2014)
- Templeton AJ, "Prognostic role of platelet to lymphocyte ratio in solid tumors : a systematic review and meta-analysis", Cancer Epidemiol Biomarkers Prev, 23, pp.1204~1212 (2014)